Inhibition of invasion and metastasis by imrecoxib and its mechanisms in lung adenocarcinoma A549 cell xenograft in nude mice

王玲婵; 崔立静; 王东昌

doi:10.19401/j.cnki.1007-3639.2017.01.001

您当前的位置：

首页 >

文章列表页 >

Inhibition of invasion and metastasis by imrecoxib and its mechanisms in lung adenocarcinoma A549 cell xenograft in nude mice

更新时间：2025-12-31

- Inhibition of invasion and metastasis by imrecoxib and its mechanisms in lung adenocarcinoma A549 cell xenograft in nude mice
- China Oncology Vol. 27, Issue 1, Pages: 1-6(2017)
- 作者机构：
  
  河北医科大学第三医院呼吸科,河北,石家庄,050051
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.01.001
  CLC：
- Published Online：23 February 2017，
  
  Published：23 February 2017
- 稿件说明：
移动端阅览
王玲婵,崔立静,王东昌,等. 艾瑞昔布抑制肺腺癌A549细胞裸鼠移植瘤侵袭和转移及其机制[J]. 中国癌症杂志, 2017, 27(1): 1-6.

王玲婵, 崔立静, 王东昌. Inhibition of invasion and metastasis by imrecoxib and its mechanisms in lung adenocarcinoma A549 cell xenograft in nude mice[J]. China Oncology, 2017, 27(1): 1-6.
王玲婵,崔立静,王东昌,等. 艾瑞昔布抑制肺腺癌A549细胞裸鼠移植瘤侵袭和转移及其机制[J]. 中国癌症杂志, 2017, 27(1): 1-6. DOI： 10.19401/j.cnki.1007-3639.2017.01.001.

王玲婵, 崔立静, 王东昌. Inhibition of invasion and metastasis by imrecoxib and its mechanisms in lung adenocarcinoma A549 cell xenograft in nude mice[J]. China Oncology, 2017, 27(1): 1-6. DOI： 10.19401/j.cnki.1007-3639.2017.01.001.

摘要

背景与目的：环氧化酶-2(cyclooxygenase-2，COX-2)与肺癌血管生成、淋巴转移相关，COX-2抑制剂能够抑制肺癌侵袭和转移。该研究探讨COX-2抑制剂艾瑞昔布能否抑制肺腺癌A549细胞裸鼠移植瘤侵袭和转移及其机制，以及与洛铂联合应用的疗效。方法：将肺腺癌A549细胞接种于30只BALB/c雄性裸鼠右侧腋部皮下，建立移植瘤模型。将造模成功裸鼠(n=29)随机分为4组：对照组(n=7)、艾瑞昔布组(n=8)、洛铂组(n=7)和艾瑞昔布联合洛铂组(n=7)。对照组灌胃等量灭菌蒸馏水及尾静脉注射等量0.9%NaCl溶液，治疗组分别给予灌胃艾瑞昔布片每日40 mg/kg及尾静脉注射洛铂每周7.5 mg/kg相应处理。每日观察裸鼠饮食、活动等一般情况。给药6周后处死裸鼠，剥取移植瘤组织。应用免疫组织化学法和real-time PCR分别检测各组肿瘤PTEN、cortactin蛋白及相应mRNA表达水平。采用单因素方差分析及非参数检验进行统计学分析。结果：最后1周发现所有裸鼠饮食、活动较之前减少，逐渐消瘦，洛铂组及联合组变化较明显。与对照组相比，艾瑞昔布组及联合组PTEN蛋白及其mRNA表达明显升高，差异有统计学意义(P均0.001)；与对照组相比，艾瑞昔布组及联合组cortactin蛋白及其mRNA表达明显降低，差异有统计学意义(P均0.001)。PTEN与cortactin蛋白、PTEN mRNA与cortactin mRNA均呈显著负相关(r=-0.660、-0.983，P均0.001)。结论：艾瑞昔布能够抑制非小细胞肺癌侵袭和转移，其作用机制可能与上调PTEN蛋白及下调cortactin蛋白表达有关。艾瑞昔布对洛铂化疗可能具有增敏作用。

Abstract

Background and purpose: Cyclooxygenase-2 (COX-2) participates in angiogenesis and lymph node metastasis of lung cancer. COX-2 inhibitors could inhibit invasion and metastasis of lung cancer. This study aimed to investigate the inhibition of invasion and metastasis by COX-2 inhibitor imrecoxib in xenograft tumor of lung adenocarcinoma A549 cell in nude mice and to explore its possible mechanisms

in addition

to observe the efficacy of imrecoxib combined with lobaplatin. Methods: Thirty male BALB/c nude mice were injected subcutaneously with A549 cells into the right axillary region to establish xenograft models. Twenty-nine successfully modeled mice were randomly divided into four groups: control group (n=7)

imrecoxib group (n=8)

lobaplatin group (n=7)

imrecoxib combined with lobaplatin group (n=7). The control group was treated with the same amount of sterile distilled water and injected with the same amount of 0.9% sodium chloride solution via caudal vein. The treatment group was treated with imrecoxib tablets 40 mg/kg per day through gavage and injected with lobaplatin 7.5 mg/kg per week via caudal vein respectively. The diet

physical activity and other normal conditions of nude mice were observed everyday. After 6 weeks

29 mice were sacrificed and transplanted tumor tissues were cut off. The expression of PTEN

cortactin protein and mRNA were detected by immunohistochemistry and real-time PCR. The data were analyzed with one-way anova and non-parametric test. Results: In the last week

the diet and physical activity of all nude mice were less than before

and they became thinner

which were more obvious among the mice in lobaplatin group and imrecoxib combined with lobaplatin group. Compared with the control group

the expression of PTEN protein and mRNA were significantly increased in imrecoxib group and imrecoxib combined with lobaplatin group (P0.001

respectively). Compared with the control group

the expression of cortactin protein and mRNA were significantly decreased in imrecoxib group and imrecoxib combined with lobaplatin group (P0.001

respectively). PTEN and cortactin protein

PTEN and cortactin mRNA had significantly negative correlation (r=-0.660

-0.983

P0.001

respectively). Conclusion: Imrecoxib can inhibit non-small cell lung cancer invasion and metastasis which may be involved in upregulating PTEN protein and reducing cortactin protein. Imrecoxib could enhance the effect of lobaplatin chemotherapy.

关键词

Keywords

references

Views

1706

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanisms of PTEN-regulated PDK1 in modulating malignant phenotypes of clear cell renal cell carcinoma

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications

A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Important clinical research progress in lung cancer in 2022

Related Author

Shuangshuang DUAN

Abudusaimaiti GULINAIZAIER

Lijun ZHANG

Miao SUN

Huibin LIU

Qiling DENG

Di SONG

Kexin XI

Related Institution

College of Pharmacy, Xinjiang Medical University, Urumqi 830000, XinJiang Uygur Autonomous Region

Clinical Trial Institution, Xinjiang Medical University Affiliated Cancer Hospital, Urumqi 830000, XinJiang Uygur Autonomous Region

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

BSL-3 Laboratory(Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰